Irina Antonijevic
Company: Triplet Therapeutics
Job title: Chief Medical Officer
Seminars:
Live Panel Q&A – Ask the Speakers your Burning Questions! 10:45 am
day: Day Two
Targeting DNA Damage Response Genes with Oligonucleotides for Therapeutic Modulation of Somatic Instability in the Brain 9:55 am
Discussing how genes in the DNA damage response (“DDR”) pathway are potent genetic modifiers of Repeat Expansion Disorders (REDs), such as Huntington disease (HD), myotonic dystrophy, spinocerebellar ataxias, and operate upstream of disease genes Outlining how Triplet targets this fundamental unifying pathway with the goal to slow somatic repeat expansion and potentially delay or prevent…Read more
day: Day Two
PANEL DISCUSSION: From Theory to Reality: How to Target the Central Nervous System with RNAi Based Therapies 2:05 pm
In the past few years, RNAi therapeutics have rocketed as a widely promising potential therapy for several diseases. With the major shift of interest to target the central nervous system, it is critical to now consider the viability of targeting the CNS for therapeutic intervention and debate the important next steps to ensure RNAi CNS…Read more
day: Day One